Clinicopathological and prognostic involvements of MCT1, MCT4 and IL7R in esophageal squamous cell carcinoma

CURRENT STATUS: POSTED

Shutao Zheng
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China
ORCiD: https://orcid.org/0000-0002-9000-0148

Qing Liu
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China

Doudou Tan
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China

Tongxue Shen
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China

Xiao Zhang
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China

Xiujuan Han
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China

Xiaomei Lu
Clinical Medical Research Institute, First Affiliated Hospital of Xinjiang Medical University, Xinjiang Uygur Autonomous Region, Urumqi, PR China

luxiaomei88@163.com Corresponding Author

DOI: 10.21203/rs.2.19750/v1

SUBJECT AREAS
KEYWORDS
MCT1, MCT4, IL7R, esophageal squamous cell carcinoma (ESCC), prognosis
Abstract

Background

MCTs, short for monocarboxylate transporters, especially MCT1 and MCT4, have been widely touched upon in a variety of immune and cancer cells; however, they have been rarely described in esophageal squamous cell carcinoma (ESCC). IL7R, receptor of interleukin 7, has been shown to operate in several cancers; though, the clinicopathological implication of IL7R expression in ESCC remains less known.

Methods

Herein, to understand the clinicopathological involvements of MCT1, MCT4 and IL7R expression in ESCC, immunohistochemistry was performed with ESCC tissue microarray comprising 86 paired ESCC and its matched normal control dots. Subsequently, statistical analyses ensued.

Results

It was shown that concomitant expression of MCT1, MCT4 and IL7R prevailed in the stromal compartment of ESCC tissues relative to the epithelial. Moreover, up-regulated MCT1 and MCT4 were markedly associated with tumor size; while IL7R was displayed to closely correlate with lymph node metastases and clinical stage. Elevated MCT1, MCT4 and IL7R were strikingly associated with adverse outcome of ESCC.

Conclusions

Together, the data we presented here indicate that MCT1/4 and IL7R were heavily involved in the oncogenesis of ESCC.

Background

Monocarboxylic acid, including lactate, pyruvate and ketone bodies, have been found to play major roles in cancer metabolism and must be transported across both the plasma and mitochondrial membranes [1], where monocarboxylate transporter (abbreviated as MCT) family actually take charge of the process. MCT family now comprises as many as 14 members, of which only the first four, that is, from MCT1 to MCT4, have been experimentally borne out to catalyze the transport of monocarboxylates, such as lactate, pyruvate and ketone bodies [1, 2], which come to be recognized
as important metabolic fuel for cancer cells. Given this, there is a need to understand the
clinicopathological as well as prognostic implication of MCT1 and MCT4 expression in ESCC, where it
has been little described surrounding MCT1 and MCT4 expression and its significance.

Lactate, as mentioned above, has been shown to be as an important metabolic fuel for normal cells in
certain physiological setting [3] and in cancer [4-6] as well. Recently, it has begun to be recognized as
active molecule capable of modulating the immune response[7-10]. The interleukin-7 receptor (IL7R),
commonly expressed in immune cells, has been suggested to be critical in survival, development and
homeostasis in the immune system[11]. Advanced genome-wide cancer studies have reported that
IL7R is genetically amplified in human esophageal squamous cell carcinoma (ESCC)[11]; yet, the
clinicopathological involvement of IL7R in ESCC remains unknown.

Herein, to learn about the clinicopathological significance of MCT1, MCT4 and IL7R expression in
ESCC, Immunohistochemistry was undertaken to concomitantly appraise the expression patterns of
these three biomarkers of our interest with ESCC tissue microarray, followed by statistical analyses
with clinicopathological variables comprising demographic, clinical stage, TNM classification and
overall prognosis. It was shown that these three biomarkers we picked up predominated in ESCC
tissues as compared with its paired normal controls and that over-expressed MCT1, MCT4 and IL7R
expression were closely related to adverse outcome and metastases of ESCC.

Methods

Human specimens

This study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Xinjiang
Medical University. Written informed consent was obtained from each participant involved. The
preparation of ESCC tissue microarrays used for the immunostaining analysis of MCT1, MCT4 and IL7R
were outsourced to Shanghai Outdo Biotech. Co. Ltd (Superchip, Shanghai, China). The tissue
microarray was composed of 90 paired ESCC tissues and its matched normal dots. Notably, 4 paired
cases of dots were missing in the experimental process. As a consequence, the real case number was
86 for each. Staging and grading of the sample tissues was graded according to hematoxylin and
eosin (H&E) staining. Histopathological diagnosis was conducted following the criteria of the World Health Organization 2017 version. None of the samples were collected from patients undergoing chemoradiotherapy before esophagectomy. The clinicopathological variables comprising demographic, clinical stage, TNM classifications, and overall survival, were documented when available.

**Immunohistochemistry (IHC)**

In brief, the ESCC tissue microarrays were deparaffinized and rehydrated. Heat-induced epitope retrieval was performed using citrate buffer (pH=6.0) and a microwave histoprocessor (Haier, Qingdao, Shandong, China), after which the tissue sections were incubated with 3% hydrogen peroxide for 10 minutes to block endogenous peroxidase activity. Tissue sections were then incubated with a primary antibody to MCT1 (Catalog number: 20139-1-AP; dilution at 1:600, Proteintech, China), MCT4 (Catalog number: 22787-1-AP; dilution at 1:400, Proteintech, China) and IL7R (Catalog number: TA327014; dilution at 1:150, Origene, Rockville, MD, USA) overnight in a humidified chamber at 4°C. Immunostaining was visualized using a labeled horseradish peroxidase (HRP)-conjugated AffiniPure goat anti-rabbit IgG antibody (Catalog number: ZB-2301; ready-to-use format; ZSGB-Bio, Beijing, China) with 3, 3’-diaminobenzidine as a chromogen, and the tissues were counterstained with hematoxylin. Primary antibodies replaced with normal rabbit anti-human IgG antibody were used as negative control. Colorectal carcinoma tissues, as has been earlier reported [12], were served as positive control for MCT1 and MCT4 expression, and lung cancer tissue[13] was picked up as positive control for IL7R expression.

**Immunoscoring**

The immunoscoring of the three biomarkers we picked out was performed under a light microscope by two pathologists (WLC and ZY, appreciated in acknowledgement). The staining patterns were scored based on the intensity and area of the positive staining, as described previously[14]. Specifically, the intensity of positive staining was scored as follows: 0, negative; 1, weak staining; 2, moderate staining; and 3, strong staining. The rate of positive cells was scored on a 0 to 4 scale: 0, 0–5%; 1, 6–25%; 2, 26–50%; 3, 51–75%; and 4, >75%. If the positive staining was homogeneous, a final
score was achieved by multiplication of the two scores above, give birth to a total range from 0 to 12. When the staining was heterogeneous, it was scored as follows: each component scored independently and summed for the results. For example, a specimen containing 25% tumor cells with moderate intensity (1 × 2 = 2), 25% tumor cells with weak intensity (1× 1 = 1), and 50% tumor cells without staining received a final score of 2 + 1 + 0 = 3. Dispute, if any, arises in the scoring will be approached by the consensus reached between the two pathologists. For statistical analysis, all the samples of ESCC were categorized into two major groups according to positive expression as follows: scores of 0 to 8 as low expression and scores of 9 to 12 as high expression.

**Statistical analysis**

Chi-square was used in clinicopathological characteristics between MCT1, MCT4 and IL7R high and low expression. Notably, when expected number was less than 5, Fisher’s exact test was applied. For survival, the start date was the beginning of treatment, either esophagectomy or chemotherapy or radiotherapy, ending with the last follow-up date or death. Overall survival was calculated using Kaplan-Meier curves, whereas survival differences between groups were examined by log rank tests. Multivariate analysis with Cox proportional-hazards modeling was performed to adjust for covariates. When P-value of <0.05 was considered statistically significant. Statistical analysis was conducted using SPSS 17.0 version (SPSS, Chicago, USA).

**Results**

**MCT1, MCT4 and IL7R predominated in the stroma of ESCC.**

To understand the expression of MCT1, MCT4 and IL7R in ESCC, IHC was conducted on ESCC tissue microarray consisting of 90 paired ESCC and its matched normal control dots. Considering the underlying problems regarding correctness and specificity that may be caused by the quality of primary antibody itself that were commercially available, we pre-examined the quality of the three primary antibodies to MCT1, MCT4 and IL7R following the approach, which is to say antigen pre-adsorption, mentioned by Hewitt SM and colleagues [15]. Pre-test result confirmed the specificity of the three primary antibodies commercially available were adequate to do their jobs (data not shown), which was corroborated by the negative control (Figure 1) and positive control (Figure 2) we
purposefully set up from the outset. Subsequently, we set out to simultaneously detect the concomitant expression of MCT1, MCT4 and IL7R with IHC. Results from IHC revealed that the positive staining of MCT1, MCT4 and IL7R were mainly membranous and slightly cytoplasmic. The distribution of MCT1, MCT4 and IL7R were mainly confined to the stroma, as opposed to epithelial where little positive staining can be detectable. Intensity of immunostaining of MCT1, MCT4 and IL7R were highly heterogeneous, varying greatly from case to case, with intensity being from negative, weak, moderate and strong in ESCC tissues (Figure 3). Besides, the immunostaining of MCT1, MCT4 and IL7R can also be present in paired normal control tissues, with the intensity of the bulk of cases being weak staining. Only few cases were moderate. Despite present in both ESCC and its matched normal controls, the staining of MCT1, MCT4 and IL7R, taken as a whole, were appreciably over-expressed in ESCC relative to normal control (Table 1), explicitly indicating the tumor-promoting roles in ESCC.

Clinicopathological involvements of MCT1, MCT4 and IL7R in ESCC.

Having seen the immunohistochemical characteristics of MCT1, MCT4 and IL7R in ESCC tissues, next we sought to analyze the clinicopathological meaning of MCT1, MCT4 and IL7R expression by Cross-Table statistical analysis. It was exhibited that compared with the paired normal control, MCT1, MCT4 and IL7R were drastically over-expressed in ESCC tissues (Table 1). As stated already, the distribution of ESCC cells with positive immunostaining of MCT1, MCT4 and IL7R were predominantly confined to the stromal compartment. Only a few cases with positive immunostaining of these three markers can be visible in epithelial. Furthermore, there was significant correlation between lymph nodes metastases versus MCT1 \( (P=0.040) \) and IL7R \( (P=0.011) \) stromal expression. Among MCT1, MCT4 and IL7R, only MCT1 was shown to be pronouncedly associated with T classification \( (P=0.005) \), tumor size \( (P=0.047) \) and clinical stage \( (P=0.029) \). What’s slightly different from MCT1 in that, MCT4 was displayed to be markedly associated with tumor size \( (P=0.044) \), yet no significant association can be identified with other clinicopathological variables. Notably, although no significant association can be reached between MCT4 stromal expression and age; there was a statistical trend towards significance \( (P=0.061) \). Regarding IL7R, stromal expression of IL7R was observed to markedly correlate with clinical stage \( (P=0.002) \) in addition to lymph nodes metastases \( (P=0.011) \). Still, no significant
association can be achieved between stromal expression of IL7R and other clinicopathological variables, including distant metastases, differentiation, T classification, tumor size and demographic information consisting of age and gender.

**Prognostic implications of MCT1, MCT4 and IL7R in ESCC.**

Next, to understand the prognostic significance of MCT1, MCT4 and IL7R expression in ESCC, Kaplan-Meier survival curve was plotted to analyze the statistical difference between patients with high versus low expression of the three biomarkers we took interested in. Kaplan-Meier survival analysis exhibited that, there was statistically significant difference between patients with high expression and low expression of MCT1, MCT4 and IL7R (Figure 2), strong indicating that up-regulated MCT1, MCT4 and IL7R expression was significantly associated with unfavorable overall prognosis in patients with ESCC. To assess the effect of MCT1, MCT4 and IL7R expression and clinicopathological variables available on prognosis, both univariate and multivariate survival analyses were undertaken. Univariate Cox regression analysis revealed that MCT1 ($P=0.001$), MCT4 ($P=0.001$) and IL7R ($P=0.001$) expression, T classification ($P=0.009$), Clinical stage ($P=0.025$), and N classification ($P=0.048$) were prognostic factors in ESCC. By using multivariate analysis, we further stringently evaluated the prognosis related factors that were shown to be significant in univariate analysis. It exhibited that MCT1 ($P=0.004$), MCT4 ($P=0.005$) and IL7R ($P=0.008$) expression and T classification ($p=0.013$), lymph node metastasis ($p=0.016$), differentiation degree ($P=0.036$) were independent prognostic factors affecting the 5-year overall survival. Notably, despite no significant association can be obtained between clinical stage and outcome, there was a statistical trend towards significance ($P=0.069$). Together, the data explicitly indicate that MCT1, MCT4 and IL7R expressions can be used as a prognostic predictor in ESCC (Table 2).

**Discussion**

In this study, MCT1, MCT4 and IL7R expression were shown to be strikingly predominant in the stroma of ESCC tissues; and that over-expressed MCT1, MCT4 and IL7R were found to be significantly linked with T classification, lymph nodes metastases and distant metastases. Moreover, these three biomarkers were analyzed to be independent prognostic factors in ESCC, strongly suggestive of their
prognostic value in ESCC.

As numerous studies have probed the biochemical or mechanistic roles of MCT1, MCT4 in the setting of cancer from different tissue origins, our aim here was not to explore their working mechanism but to analyze the clinicopathological implications of their expression in ESCC. Immunohistochemical characteristics were quantitatively analyzed of ESCC cells expressing MCT1, MCT4 and IL7R, exhibiting that immunostaining of MCT1, MCT4 and IL7R were observed mainly on cytoplasmic membrane and slightly in cytoplasm. In order to analyze the correlation between these three markers we take interested in, four sets of ESCC tissue microarrays were used on which dots of each set were entirely obtained from the same site of tissue serially sectioned. To rule out the possibility that the three biomarkers could be expressed by other types of cells, other than ESCC cells we focused upon only, within the tumor microenvironment; Hematoxylin and eosin (H&E) staining was performed and frequently reviewed when immunoscoring. Given this, the expression of MCT1, MCT4 and IL7R was thus unlikely to be overestimated in ESCC tissues in our setting.

MCT1, also known as SLC16A1, has been reported to take charge of influx of lactate. In stark contrast, physiologically, MCT4 was found to be in charge of efflux of lactate, as systemically reviewed by Halestrap AP[16]. Although extensive studies can be readily available regarding the MCT1 in cancers of different types; it has been little described in esophageal cancer with the exception of two recent related reports[17, 18]: one about MCT1 expression in Barrett's esophagus and adenocarcinoma, the other ESCC. Analysis from previous investigations concerning MCT1 in cancers, regardless of different types[19-22], revealed that MCT1 prevailed or predominantly over-expressed in cancerous tissues as compared with normal controls and up-regulated MCT1 was found to be linked with poor outcome as well as tumor metastases, which was fully in agreement with our observations in ESCC of our own case. What’s congruent with our description with regard to MCT1 is that, in a recent study [18] by Chen X and colleagues, MCT1 was exhibited to be an independent prognostic factor in ESCC. What’s different from the study by Chen X et al [18] in that, there was short of functional analysis data of MCT1 in our setting with cell culture system. Examination of data from these aforementioned literatures along with our own findings about MCT1 in ESCC, explicitly suggested the prognostic value
of MCT1 in malignancies, irrespective of their types. Much like MCT1, MCT4 comes from the same family as MCT1 does. But, in the case of mediating the lactate transport, it was totally opposite of MCT1. MCT4 was mainly involved in the release of lactate or “efflux”, whereas uptake of lactate or “influx” was chiefly mediated by MCT1, as extensively reviewed[1, 23]. Relative to the quantity of studies of MCT1, MCT4 seemed to be received more attention than those of MCT1 in cancer. Studies undertaken in the area of cancer abound, unraveling that MCT4 was uniformly seen to be strikingly up-regulated in cancerous tissues compared with normal control; and elevated MCT4 was correlated with unfavorable outcome [19, 21, 24-26]. By contrast, there were only two pieces of literature with regard to MCT4 in esophageal cancer until now[17, 27]. In our findings, MCT4 was exhibited to be an independent prognostic factor of ESCC, whereas no significant correlation with lymph nodes metastases was observed, was partly supported by the replicated observation made by Cheng B et al in ESCC[27]. Moreover, we also noted that MCT4 expression was found to be closely related with tumor size, as MCT1 was. It may be that more lactate transporters could be needed so as to suit the metabolic reprogram with the development and progression of ESCC cells.

Scant data has been available on the clinicopathological implications of IL7R in solid tumors, not to mention in ESCC; although several lines of evidence existed concerning genetic polymorphisms or mutations of IL7R in the context of hematopoietic lymphoma[28]. IL7R was not necessarily expressed in immune cells; it can also be expressed in cancer cells, such ESCC cells [11] and hepatoma cells [29]. Although there was one similar study has been replicated regarding IL7R in ESCC[11]; the clinicopathological involvement of IL7R currently remains unknown. In our study, IL7R was shown to be over-expressed in ESCC tissues relative to paired normal controls, which was highly consistent with what has been reported by Kim MJ and associates[11]. Unfortunately, there has been a shortage of clinicopathological analysis of IL7R expression in their study. Hinted from the limited data available in the above studies, these findings suggest that IL7R can work oncogenically in malignant tumors. Our observation that up-regulated IL7R was closely linked with clinical stage and shorter overall prognosis, further supports the oncogenic function of IL7R in tumors.
Current opinion holds that Inflammation is associated with the accumulation of lactate at sites of tumor-growth[30]. Several tumors and inflammatory sites have displayed accumulation of lactate and altered expression of its transporters, which is strongly suggestive of the heavy involvement of lactate transporters in cancer and inflammation[30]. In our study, despite we failed to analyze the lactate concentration on the ESCC tissue microarray that we used to concomitantly assess the expression of MCT1, MCT4 and IL7R owing to the technical limitation; over-expressed MCT4 can mean the release of lactate would be much more active than it should be. As a result, there will not be surprising that more lactate released from ESCC cells could stimulate inflammatory microenvironment in a way, thereby contributing to the up-regulation of IL7R of ESCC cells. More recently, a piece of evidence showing that lactate production was dramatically enhanced after colorectal cancer cells were treated with IL6 [31], strengthens the conjecture we raised here. Based on the observation, it can be safely reasoned that elevated IL7R may also boost the lactate yield in ESCC cells, which consequently may require more lactate transporters, such as MCT1 and MCT4, in order to suit any variation caused by lactate in tumor microenvironment. Of course, the hypothesis we posed here needs to be tested experimentally in the following. On the other hand, in consideration of lymphocyte that infiltrates the ESCC tissues can also express these three markers, it is therefore somewhat difficult to control the real expression of MCT1/4 and IL7R only in ESCC cells. As for the lymphocyte that infiltrates the ESCC tissues that may also express MCT1/4 and IL7R, which beyond the scope of our investigation.

Conclusion

In conclusion, our study presented that expression of MCT1, MCT4 and IL7R was closely linked with the adverse outcome of ESCC, suggesting that lactate transporters MCT1/4 and IL7R were heavily involved in the oncogenesis of ESCC.

Declarations

Funding

The present study was supported in part from National Science Foundation of China (No. 81960552, U1603284, and U1303321), Opening Project from State Key Laboratory of Pathogenesis, Prevention,
and Treatment of Central Asian High Incidence Diseases (SKL-HIDCA-2017-13), and from Science and Technology Aid Xinjiang Plan of the Xinjiang Uygur Autonomous Region (No.2018E02067).

**Availability of data and materials**

The datasets used and/or analyzed during this study are available from the corresponding author on reasonable request.

**Authors’ contributions**

STZ performed all the experiment and drafted the manuscript, QL did some favours in immunohistochemistry, DDT and TXS aided in providing the reagents involved, XZ and XJH helped analyzing the statistical analysis, XML was in charge of the whole study.

**Competing interests**

The authors declare no conflict of interest.

**Consent for publication**

Not applicable

**Ethics approval and consent to participate**

The study was approved by the Medical Ethics Committee of the First Affiliated Hospital of Xinjiang Medical University.

**Acknowledgements**

We thanked the pathologists Wenli Cui and Yan Zhao serving in the department of Pathology, in the First Affiliated Hospital of Xinjiang Medical University, for the great favor they did for us in the immunoscopying of slides and providing positive control tissues.

**Abbreviations**

MCTs, monocarboxylate transporters; ESCC, esophageal squamous cell carcinoma; IL7R, interleukin 7 receptor; IHC, Immunohistochemistry; HRP, horseradish peroxidase; SPSS, Statistical Product and Service Solutions; H&E, Hematoxylin and eosin.

**References**

1. Halestrap AP: **Monocarboxylic acid transport**. Comprehensive Physiology 2013, 3(4):1611-1643.
2. Halestrap AP, Meredith D: The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. *Pflugers Archiv : European journal of physiology* 2004, **447**(5):619-628.

3. Dienel GA: Lactate shuttling and lactate use as fuel after traumatic brain injury: metabolic considerations. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism* 2014, **34**(11):1736-1748.

4. Bonuccelli G, Tsirigos A, Whitaker-Menezes D, Pavlides S, Pestell RG, Chiavarina B, Frank PG, Flomenberg N, Howell A, Martinez-Outschoorn UE et al: Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. *Cell cycle* 2010, **9**(17):3506-3514.

5. Feron O: Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. *Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology* 2009, **92**(3):329-333.

6. Faubert B, Li KY, Cai L, Hensley CT, Kim J, Zacharias LG, Yang C, Do QN, Doucette S, Burguete D et al: Lactate Metabolism in Human Lung Tumors. *Cell* 2017, **171**(2):358-371 e359.

7. Pucino V, Bombardieri M, Pitzalis C, Mauro C: Lactate at the crossroads of metabolism, inflammation, and autoimmunity. *European journal of immunology* 2017, **47**(1):14-21.

8. Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, Matos C, Bruss C, Klobuch S, Peter K et al: LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. *Cell metabolism* 2016, **24**(5):657-671.

9. Angelin A, Gil-de-Gomez L, Dahiya S, Jiao J, Guo L, Levine MH, Wang Z, Quinn WJ, 3rd,
Kopinski PK, Wang L et al: **Foxp3 Reprograms T Cell Metabolism to Function in Low-Glucose, High-Lactate Environments.** *Cell metabolism* 2017, **25**(6):1282-1293 e1287.

10. Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, Cyrus N, Brokowski CE, Eisenbarth SC, Phillips GM et al: **Functional polarization of tumour-associated macrophages by tumour-derived lactic acid.** *Nature* 2014, **513**(7519):559-563.

11. Kim MJ, Choi SK, Hong SH, Eun JW, Nam SW, Han JW, You JS: **Oncogenic IL7R is downregulated by histone deacetylase inhibitor in esophageal squamous cell carcinoma via modulation of acetylated FOXO1.** *International journal of oncology* 2018, **53**(1):395-403.

12. Pinheiro C, Longatto-Filho A, Scapulatempo C, Ferreira L, Martins S, Pellerin L, Rodrigues M, Alves VA, Schmitt F, Baltazar F: **Increased expression of monocarboxylate transporters 1, 2, and 4 in colorectal carcinomas.** *Virchows Archiv : an international journal of pathology* 2008, **452**(2):139-146.

13. Lindskog C, Edlund K, Mattsson JS, Micke P: **Immunohistochemistry-based prognostic biomarkers in NSCLC: novel findings on the road to clinical use?** *Expert review of molecular diagnostics* 2015, **15**(4):471-490.

14. Wu ZY, Chen T, Zhao Q, Huang JH, Chen JX, Zheng CP, Xu XE, Wu YJ, Xu LY, Li EM: **Altered expression of endogenous soluble vascular endothelial growth factor receptor-2 is involved in the progression of esophageal squamous cell carcinoma.** *The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society* 2013, **61**(5):340-347.

15. Hewitt SM, Baskin DG, Frevert CW, Stahl WL, Rosa-Molinar E: **Controls for immunohistochemistry: the Histochemical Society's standards of practice for**
validation of immunohistochemical assays. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society 2014, 62(10):693-697.

16. Halestrap AP, Price NT: The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. The Biochemical journal 1999, 343 Pt 2:281-299.

17. Huhta H, Helminen O, Palomaki S, Kauppila JH, Saarnio J, Lehenkari PP, Karttunen TJ: Intratumoral lactate metabolism in Barrett's esophagus and adenocarcinoma. Oncotarget 2017, 8(14):22894-22902.

18. Chen X, Chen X, Liu F, Yuan Q, Zhang K, Zhou W, Guan S, Wang Y, Mi S, Cheng Y: Monocarboxylate transporter 1 is an independent prognostic factor in esophageal squamous cell carcinoma. Oncology reports 2019, 41(4):2529-2539.

19. Cao YW, Liu Y, Dong Z, Guo L, Kang EH, Wang YH, Zhang W, Niu HT: Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis. Urologic oncology 2018, 36(6):311 e315-311 e325.

20. Luz MC, Perez MM, Azzalis LA, Sousa LV, Adami F, Fonseca FL, Alves BD: Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers. International journal of molecular sciences 2017, 18(4).

21. Almeida L, Silva R, Cavadas B, Lima J, Pereira L, Soares P, Sobrinho-Simoes M, Lopes JM, Maximo V: GLUT1, MCT1/4 and CD147 overexpression supports the metabolic reprogramming in papillary renal cell carcinoma. Histology and histopathology 2017, 32(10):1029-1040.

22. Choi JW, Kim Y, Lee JH, Kim YS: Prognostic significance of lactate/proton
symporters MCT1, MCT4, and their chaperone CD147 expressions in urothelial carcinoma of the bladder. *Urology* 2014, **84**(1):245 e249-215.

23. Draoui N, Feron O: *Lactate shuttles at a glance: from physiological paradigms to anti-cancer treatments*. *Disease models & mechanisms* 2011, **4**(6):727-732.

24. Pinheiro C, Miranda-Goncalves V, Longatto-Filho A, Vicente AL, Berardinelli GN, Scapulatempo-Neto C, Costa RF, Viana CR, Reis RM, Baltazar F et al: *The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4*. *Cell cycle* 2016, **15**(11):1462-1470.

25. Gao HJ, Zhao MC, Zhang YJ, Zhou DS, Xu L, Li GB, Chen MS, Liu J: *Monocarboxylate transporter 4 predicts poor prognosis in hepatocellular carcinoma and is associated with cell proliferation and migration*. *Journal of cancer research and clinical oncology* 2015, **141**(7):1151-1162.

26. Gotanda Y, Akagi Y, Kawahara A, Kinugasa T, Yoshida T, Ryu Y, Shiratsuchi I, Kage M, Shirouzu K: *Expression of monocarboxylate transporter (MCT)-4 in colorectal cancer and its role: MCT4 contributes to the growth of colorectal cancer with vascular endothelial growth factor*. *Anticancer research* 2013, **33**(7):2941-2947.

27. Cheng B, Chen X, Li Y, Huang X, Yu J: *Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma*. *Oncology reports* 2018, **40**(5):2906-2915.

28. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, Paganin M, Tritapoe J, Hixon JA, Silveira AB, Cardoso BA et al: *Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia*. *Nature genetics* 2011, **43**(10):932-939.

29. Kong F, Hu W, Zhou K, Wei X, Kou Y, You H, Zheng K, Tang R: *Hepatitis B virus X protein promotes interleukin-7 receptor expression via NF-kappaB and*
Notch1 pathway to facilitate proliferation and migration of hepatitis B virus-related hepatoma cells. *Journal of experimental & clinical cancer research : CR* 2016, **35**(1):172.

30. Pucino V, Cucchi D, Mauro C: Lactate transporters as therapeutic targets in cancer and inflammatory diseases. *Expert opinion on therapeutic targets* 2018, **22**(9):735-743.

31. Zhang S, Li J, Xie P, Zang T, Shen H, Cao G, Zhu Y, Yue Z, Li Z: STAT3/c-Myc Axis-Mediated Metabolism Alternations of Inflammation-Related Glycolysis Involve with Colorectal Carcinogenesis. *Rejuvenation research* 2019, **22**(2):138-145.

Tables

Table 1. The clinicopathological involvements of MCT1, MCT4 and IL7R in ESCC.
| Variables          | N | AN T | MCT1 expression | χ² | P | MCT4 expression | χ² | P | IL7R expression | χ² | P |
|--------------------|---|------|-----------------|----|---|-----------------|----|---|-----------------|----|---|
| High expression    | High | Low | χ² | P | High | Low | χ² | P | High | Low | χ² | P |
| ANT                | 8 | 26  | 60 | 17.0 | 0 | 35  | 5  | 10.291 | 0 | 30  | 5  | 38.222 | 0 |
| ESCC               | 6 | 53  | 33 | 0    | 0 | 56  | 3  | 0     | 0 | 71  | 1  | 0    | 0 |
| Gender             | 6 | 18  | 8  | 1.17  | 9 | 0    | 0 | 0.001 | 1 | 50  | 1  | 0.492 | 0 |
| Male               | 6 | 48  | 12 | 0.00  | 2 | 40  | 1  | 3.891 | 0 | 47  | 8  | 1.660 | 0 |
| Female             | 2 | 18  | 8  | 0.00  | 2 | 17  | 9  | 0     | 0 | 20  | 6  | 0.22  | 5 |
| Age(years)         | 1 | 34  | 21 | 0.00  | 2 | 40  | 1  | 3.891 | 0 | 47  | 8  | 1.660 | 0 |
| ≤60                | 3 | 19  | 12 | 0.00  | 2 | 17  | 9  | 0     | 0 | 20  | 6  | 0.22  | 5 |
| Clinical stage     | 6 | 33  | 28 | 5.03  | 1 | 37  | 2  | 1.838 | 0 | 55  | 6  | 10.654 | 0 |
| I-II               | 2 | 20  | 5  | 0.00  | 2 | 19  | 6  | 2     | 1 | 15  | 1  | 0     | 0 |
| III                | 2 | 20  | 5  | 0.00  | 2 | 19  | 6  | 2     | 1 | 15  | 1  | 0     | 0 |
| T classification   | 4 | 24  | 25 | 7.70  | 5 | 30  | 1  | 0.759 | 0 | 39  | 1  | 0.245 | 0 |
| T1-T2              | 9 | 24  | 25 | 7.70  | 5 | 30  | 1  | 0.759 | 0 | 39  | 1  | 0.245 | 0 |
| T3-T4              | 3 | 29  | 8  | 0.00  | 2 | 26  | 1  | 0     | 0 | 31  | 6  | 0.78  | 8 |
| T classification   | 4 | 24  | 12 | 6.13  | 6 | 6    | 6  | 6.229 | 0 | 9   | 3  | 0.627 | 0 |
| N classification   | 3 | 16  | 18 | 5.04  | 7 | 19  | 1  | 2.111 | 0 | 23  | 1  | 7.019 | 0 |
| N0                 | 4 | 16  | 18 | 5.04  | 7 | 19  | 1  | 2.111 | 0 | 23  | 1  | 7.019 | 0 |
| N1-N3              | 2 | 37  | 15 | 0.00  | 2 | 37  | 1  | 0.00  | 2 | 37  | 1  | 0.00  | 2 |
| Tumor size (cm³)   | 3 | 26  | 14 | 0.40  | 6 | 27  | 1  | 1.891 | 0 | 35  | 5  | 2.496 | 0 |
| 1—3                | 5 | 38  | 12 | 0.00  | 2 | 38  | 1  | 0.00  | 2 | 38  | 1  | 0.00  | 2 |
| 3                  | 4 | 20  | 14 | 0.00  | 2 | 20  | 1  | 0.00  | 2 | 20  | 1  | 0.00  | 2 |
| Gross classification| 4 | 26  | 14 | 0.40  | 6 | 27  | 1  | 1.891 | 0 | 35  | 5  | 2.496 | 0 |
| Ulcerative         | 9 | 5   | 4  | 0.00  | 2 | 5   | 4  | 0.00  | 2 | 5   | 4  | 0.00  | 2 |
| Fungating          | 3 | 22  | 15 | 0.00  | 2 | 22  | 1  | 0.00  | 2 | 22  | 1  | 0.00  | 2 |
| Medullary          | 7 | 22  | 15 | 0.00  | 2 | 22  | 1  | 0.00  | 2 | 22  | 1  | 0.00  | 2 |

Note: ANT, adjacent normal tissue; Fisher’s exact test was used in cells where expected value was less than 5 in the contingency table.

Table 2. Univariate and multivariate Cox regression analysis of variables related with the prognosis in
| Variables                          | Univariate |                      |                  | Multivariate |                      |                  |
|-----------------------------------|------------|----------------------|------------------|--------------|----------------------|------------------|
|                                   | HR (95% CI)| P                    |                  | HR (95% CI)  | P                    |                  |
| Gender                            |            |                      |                  |              |                      |                  |
| male vs female                    | 1.212 (0.486-2.225) | 0.474                |                  |              |                      |                  |
| Age                               |            |                      |                  |              |                      |                  |
| ≤60 vs >60                        | 0.867 (0.505-1.486) | 0.602                |                  |              |                      |                  |
| Tumor size (cm³)                  |            |                      |                  |              |                      |                  |
| ≤3 vs >3                          | 0.659 (0.341-1.356) | 0.274                |                  |              |                      |                  |
| T classification                  |            |                      |                  |              |                      |                  |
| T₁-T₂ vs T₃-T₄                    | 0.375 (0.184-0.755) | 0.009                | 0.411 (0.165-0.947) |              |                      |                  |
| Differentiation                   |            |                      |                  |              |                      |                  |
| Well/moderate-poor                | 0.634 (0.371-1.362) | 0.239                |                  |              |                      |                  |
| Clinical stage                    |            |                      |                  |              |                      |                  |
| I-II vs III                       | 0.517 (0.314-0.926) | 0.025                | 0.600 (0.345-1.041) |              |                      |                  |
| N classification                  |            |                      |                  |              |                      |                  |
| N₀ vs N₁-N₃                       | 2.023 (0.947-4.180) | 0.048                |                  |              |                      |                  |
| MCT1 expression                   |            |                      |                  |              |                      |                  |
| High vs Low                       | 0.334 (0.169-0.523) | 0.001                | 0.338 (0.212-0.727) |              |                      |                  |
| MCT4 expression                   |            |                      |                  |              |                      |                  |
| High vs Low                       | 0.271 (0.142-0.519) | 0.001                | 0.410 (0.222-0.767) |              |                      |                  |
| IL7R expression                   |            |                      |                  |              |                      |                  |
| High vs Low                       | 0.216 (0.124-0.557) | 0.001                | 0.364 (0.157-0.827) |              |                      |                  |

Note: vs, versus; HR, hazard ratio; CI, confidence interval.

Figures
Figure 1

Exhibited was the negative control set up in the immunohistochemistry in ESCC. The primary antibody was replaced with normal rabbit IgG (Catalog number: ZM-0491; clonality:...
4E3; ZSGB-Bio, Beijing, China), diluted at 1:150, was as negative control. The original magnification was 50 fold; magnification of the field of interest was 400 fold. H&E, hematoxylin-eosin.

![Colorectal carcinoma and Lung carcinoma](image)

**Figure 2**

Presented was the positive control set up for immunohistochemical detection of MCT1, MCT4 and IL7R. Notably, here the lung cancer referred to was, actually, lung squamous cell carcinoma. The original magnification was 50 fold; magnification of the field of interest where boxed in yellow was 400 fold.
Figure 3

Shown were immunohistochemical characteristics of MCT1, MCT4 and IL7R using the serial sections cut from the same tissue blocks of ESCC and its paired normal control. Distribution of ESCC cells expressing MCT1, MCT4 and IL7R was mainly restricted to stromal compartment. The original magnification was 50 fold; magnification of the field of interest was 400 fold. H&E, hematoxylin-eosin.
Prognostic significance of MCT1, MCT4 and IL7R expression in ESCC. Log-rank test was applied to analyze the statistical difference between high and low expression of MCT1, MCT4 and IL7R.